ANC-501 in the Treatment of Adults With Major Depressive Disorder

Ancora Biotech (EmbarkNeuro)

Status and phase

Completed

Phase 2

Conditions

Major Depressive Disorder

Treatments

Drug: ANC-501

Study type

Interventional

Funder types

Industry

Identifiers

NCT05439603

ANC501D0005

Details and patient eligibility

About

A Phase 2 Study of ANC-501 in the treatment of adults with Major Depressive Disorder

Full description

This is a single-arm, open-label Phase 2 study to assess the safety, tolerability, pharmacokinetics (PK), and activity of ANC-501 oral capsules as adjunctive treatment in subjects diagnosed with major depressive disorder (MDD)

Enrollment

15 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult male or female between 18 and 65 years of age, inclusive.
Diagnosis of current episode of major depressive disorder (MDD) at least 8 weeks prior to screening, confirmed by Structured Clinical Interview for DSM-5 - Clinical Trials Version (SCID-5-CT).
Have not responded to their current antidepressant therapy or to dose adjustment/treatment changes following a loss of response to their current antidepressant therapy.
Receiving a stable dose of the same antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI], bupropion or trazodone monotherapy) for the current episode for at least 6 weeks of continuous treatment, which can include some or all of the screening period, with 4 weeks on a stable dose prior to day 1 and has an inadequate response (<50% improvement) using the MGH ATRQ.
MADRS total score of ≥26 at screening and Day 1 (prior to dosing).
12-hour urine cortisol level >22.7 nmol/L(greater than or equal to 8.3 mcg/L).

Exclusion criteria

Inadequate response to >2 prior ADTs (not including current antidepressant) of at least 6 weeks duration each for the episode current at screening.
Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
Administration of drugs to treat psychiatric or neurologic conditions that have not been taken at a stable dose for at least 4 weeks prior to day 1.
Significant findings on ophthalmic examination including, Best Corrected Visual Acuity (BCVA) worse than 20/30 or, in the opinion of the ophthalmologist or optometrist, any cataract that may become clinically significant and/or need surgical intervention during the course of the trial.